Patient or Disabled Group
FDA Approves Xolair (Omalizumab) for Reducing Severe Outcomes from Multiple Food Allergies
Xolair, United States Food and Drug Administration, omalizumab, Hypersensitivity, Food, Reduced, Severe (severity modifier)
FDA Approves Amtagvi as the First One-time Cell Therapy for Solid Tumors: A Groundbreaking TIL Immunotherapy for Advanced Melanoma
Amtagvi, Solid Neoplasm, United States Food and Drug Administration, Lymphocytes, Tumor-Infiltrating
Inventiva Halts Enrollment in Phase 3 MASH Study Following Patient Raised Liver Enzyme Incident
Clinical Research, lanifibranor, Incident
Neurona Raises $120M Bolstered by Promising Early-Stage Data for Epilepsy Cell Therapy NRTX-1001
Epilepsy, NRTX-1001, Seizures, Neurona, Cell Therapy
With subpar sales for Leqembi, Eisai delays Alzheimers patient goal deadline
Leqembi, Alzheimer’s Disease, Eisai, subpar sales
UPDATE: Vertex beats own record in cystic fibrosis as next-gen treatment goes up against Trikafta
Cystic Fibrosis, Trikafta, vanza, Vertex, next-gen, Records
Lilly reports mid-stage win for tirzepatide in fatty liver disease
tirzepatide, Nonalcoholic Steatohepatitis, liver scarring, Lilly reports, MASH, Clinical Trials
4DMT’s Gene Therapy Reduces Eylea Injections, Advancing Plans for Phase 3 Trial in Wet AMD
Glycogen storage disease type II, 4DMT, gene therapy, Trial Phase
Merck details win for Keytruda in bladder cancer after surgery
Keytruda, Malignant neoplasm of urinary bladder, Surgery specialty
Shanghai startup’s gene therapy restores hearing in five deaf children, running ahead of Lilly and Regeneron trials
Child, Hearing, Hearing Impaired Persons, gene therapy